Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.31 |
| ▸ | XDH | P47989 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20681270 | 0.87 | RXRA (0.35) | L3MBTL1GABRA1GABRG2GABRB3XDH | |
| SCHEMBL25139089 | 0.85 | MAPK1 (0.38) | L3MBTL1GABRA1GABRG2GABRB3NLRP3 | |
| SCHEMBL30791046 | 0.80 | GLA (0.37) | NLRP3XDH | |
| SCHEMBL20681114 | 0.80 | GLA (0.37) | NLRP3XDH | |
| SCHEMBL21962095 | 0.79 | NLRP3 (0.47) | NLRP3 | |
| SCHEMBL23692299 | 0.79 | — | — | |
| SCHEMBL22773936 | 0.78 | GABRA1 (0.35) | GABRA1GABRG2GABRB3TSHRSMN1; SMN2 | |
| SCHEMBL21535431 | 0.78 | MAOA (0.36) | GABRA1GABRG2GABRB3AR | |
| SCHEMBL8132569 | 0.72 | GABRA1 (0.55) | GABRA1GABRG2GABRB3TSHRSMN1; SMN2 | |
| SCHEMBL21962203 | 0.72 | GPR35 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210395241-A1 | NLRP MODULATORS | NOVARTIS INFLAMMASOME RESEARCH, INC. | 2021-12-23 | — | — | US | disclosed |
| CN-113613721-A | NLRP modulators | 诺华股份有限公司 | 2021-11-05 | — | — | CN | disclosed |
| EP-3817815-A1 | NLRP MODULATORS | Novartis AG (CH) | 2021-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395241-A1 | NLRP MODULATORS | NLRP1, NLRP3, NOD1 | L3MBTL1 4774/4885GABRA1 2105/4885GABRG2 2456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.